Chmura, S. J., Winter, K. A., Salama, J. K., Woodward, W. A., Borges, V. F., Al-Hallaq, H. A., … White, J. R. (2016). NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. In Journal of Clinical Oncology (Vol. 34, pp. TPS1098–TPS1098). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps1098

Chmura, Steven J., Kathryn A. Winter, Joseph Kamel Salama, Wendy A. Woodward, Virginia F. Borges, Hania A. Al-Hallaq, Martha Matuszak, et al. “NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.” In Journal of Clinical Oncology, 34:TPS1098–TPS1098. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps1098.

Chmura SJ, Winter KA, Salama JK, Woodward WA, Borges VF, Al-Hallaq HA, et al. NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS1098–TPS1098.

Chmura, Steven J., et al. “NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS1098–TPS1098. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps1098.

Chmura SJ, Winter KA, Salama JK, Woodward WA, Borges VF, Al-Hallaq HA, Matuszak M, Jaskowiak NT, Milano MT, Bandos H, White JR. NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS1098–TPS1098.